Table 2 summarizes the current knowledge regarding MLPA evaluation of CNVs in our regions of interest (the 22q11.2 region and GATA4, TBX5, NKX2-5, BMP4, and CRELD1 genes) in different populations of CHD patients. This evidence concerns the gene TBX5 and coronary artery disorder.